For the quarter ended September 2025, Agilon Health (AGL) reported revenue of $1.44 billion, down 1.1% over the same period last year. EPS came in at -$0.27, compared to -$0.29 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.43 billion, representing a surprise of +0.57%. The company delivered an EPS surprise of -50%, with the consensus EPS estimate being -$0.18.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Avg. Medicare Advantage Members: 510,000 compared to the 500,250 average estimate based on two analysts.
- Revenues- Medical services: $1.43 billion compared to the $1.42 billion average estimate based on four analysts. The reported number represents a change of -1.1% year over year.
- Revenues- Other operating: $2.88 million versus the four-analyst average estimate of $3.12 million. The reported number represents a year-over-year change of -10.9%.
View all Key Company Metrics for Agilon here>>>
Shares of Agilon have returned -27.7% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilon Health, Inc. (AGL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
